The Michael J. Fox Foundation Parkinson's Podcast

Latest Episodes:

Podcast: The State of Parkinson’s Disease Research Feb 12, 2013

Show notes

2013 could be a pivotal year in PD research, with expected developments on a variety of fronts. In this podcast, Dave Iverson speaks with Foundation staffers about some of that lies ahead.

Mentioned in this episode:

All Grit. No Quit. is our bold Campaign to raise $2.5 billion by 2028. This is our biggest push yet toward a world without Parkinson's and we need to bring the full force of our community to meet this moment. Whatever brings you here, you can be a part of accelerating what comes next. michaeljfox.org/campaign/all-grit-no-quit

Podcast: The Decision to Get Genetically Tested Aug 22, 2012

Show notes

Emerging evidence over the past 15 years has led researchers to believe that genetics plays a far greater role in Parkinson’s disease (PD) than was once thought.

Mentioned in this episode:

Podcast: Engaged Parkinson's Patients Are the Answer to a Cure Mar 28, 2012

Show notes

Patients have always been at the heart of what we do at The Michael J. Fox Foundation. Our dedication to improving patients’ quality of life has shaped our research priorities.

Mentioned in this episode:

Podcast: Limiting On-Off Periods in Parkinson's Medications Mar 09, 2012

Show notes

While levodopa is the gold standard therapy for Parkinson's disease (PD), current delivery methods have their limitations.

Mentioned in this episode:

Podcast: What is the Connection Between Genetics and Environment in Parkinson's? Mar 08, 2012

Show notes

Understanding the genetics of Parkinson’s disease could be a game changer in developing new treatments for the disease. Especially when it comes to two genetic targets: LRRK2 and alpha-synuclein.

Mentioned in this episode:

Podcast: Teva Seeks Label Change for Azilect Jan 02, 2012

Show notes

This fall, The FDA recommended that Teva Neuroscience’s drug rasagiline, brand name Azilect, should not be granted status “to slow the clinical progression of PD.”

Mentioned in this episode:

Podcast: A Vaccine Approach to Treating Parkinson's Disease Dec 18, 2011

Show notes

This past October, Austrian biotech AFFiRiS announced $1.5 million in funding from MJFF for an early stage clinical trial of a first-of-its-kind vaccine approach to treating Parkinson's disease (PD).

Mentioned in this episode: